Zydus Lifesciences has obtained approval from the United States Food and Drug Administration (USFDA) to market a generic version of Ketoconazole Shampoo, an antifungal drug employed in the treatment of dandruff and other fungal infections. This achievement enables the company to further establish its presence in the US pharmaceutical industry with a popular treatment for prevalent scalp and skin diseases.
The approved drug product, having 2% Ketoconazole, will be produced at Zydus’s topicals manufacturing unit in Changodar, Ahmedabad. Being effective against conditions like seborrheic dermatitis and resistant dandruff, Ketoconazole Shampoo is a long-tested remedy in the field of dermatology.
As of January 2025, based on sales data from IQVIA MAT, the Ketoconazole Shampoo market in the US clocked annual revenues of around USD 68.89 million, an indication of the high level of demand for the drug. The approval constitutes a strategic gain for Zydus Lifesciences as the company further boosts its portfolio of dermatological formulations in the global market.
After the announcement, Zydus Lifesciences shares registered a marginal increase, trading at ₹903.10 per share on the Bombay Stock Exchange (BSE), up 0.22%. The approval further solidifies the company’s focus on increasing access to high-quality and affordable therapies while enhancing its global presence in the pharmaceutical industry.
